Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...

Economists begin by asking what would happen in a completely free market. Then we ask whether government intervention of some ...

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Former congressman Michael Burgess opposes a White House executive order that ties U.S. drug prices to the artificially low, ...

According to brokerage Jefferies, the average drug development cycle spans 8 to 10 years, with success rates below 10% and ...

GenScript, a global leader in life science research tools and services support, has expanded its mRNA synthesis and ...

A February executive order on pharmaceutical price transparency does nothing to change the incentives that keep costs opaque. But drug companies and other stakeholders would reap the benefits of such ...

President Trump has elevated an issue Democrats have been jawboning about for years. The president issued an executive order ...

The president said that, because of his executive order, prescription drug prices would be cut “almost immediately.” Here's ...

Discussion around international reference pricing (IRP) is intensifying as policymakers search for ways to address persistently high prescription drug costs in the United States. With news of the ...